Compare Chipotle Mexican Grill, Inc. (CMG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.29 (market cap $40.67B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 22.8× Recursion Pharmaceuticals Inc's market cap, and Chipotle Mexican Grill, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CMG | RXRX | |
|---|---|---|
Market Cap | $40.67B | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $6.79 |
52-Week Low | $28.17 | $2.84 |
Enterprise Value | $45.42B | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.81, down 2.67% amid food safety concerns. The stock shows bearish technical signals with strong analyst support (70% buy ratings) and a $42.17 consensus target. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $0.33 exceeding estimates. Revenue growth remains steady, climbing from $8.6B in 2022 to $11.9B in 2025, though net income margin compressed to 11.42% in 2026 from 13.55% in 2024.
Despite strong fundamentals and analyst optimism, CMG faces near-term headwinds from salmonella outbreaks and fraud investigations. The stock's premium valuation (P/E 29.76) requires sustained execution amid operational challenges. Long-term growth trajectory remains intact, but current sentiment is cautious due to food safety issues and legal scrutiny.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
